The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1611
November 16, 2020
View Complete Issue         Table of Contents 2019 
Empagliflozin (Jardiance) for Heart Failure
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Empagliflozin (Jardiance) for Heart Failure
November 16, 2020 (Issue: 1611)
In a randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance – Boehringer Ingelheim/Lilly) reduced the composite risk of cardiovascular death or hospitalization for worsening heart...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Empagliflozin (Jardiance) for Heart Failure
Article code: 1611b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.